A Biotech With 94.53% Potential Upside
Rapport Therapeutics, Inc. (RAPP), a clinical-stage biopharmaceutical company based in Boston, Massachusetts, is making waves in the biotechnology sector with its promising pipeline focused on central nervous system (CNS) disorders. With a market capitalization of $1.28 billion, this company is capturing the interest of investors, especially given its substantial potential upside of 94.53%, as indicated by recent analyst ratings.
Specializing in the development of small molecule medicines, Rapport Therapeutics is at the forefront of innovation. Its lead product candidate, RAP-219, is designed to inhibit TARPy8-containing AMPARs with extraordinary precision. This investigational drug is aimed at treating focal epilepsy and other…
